SLFN11 and lung carcinoma: Notably, promoter hypermethylation of SLFN11, which is a key source for SLFN11 inactivation, also predicts worse drug-response in platinum-based chemotherapy in ovarian or lung cancer patients, as well as a poor clinical outcome biomarker [125].